Skip to main content
Premium Trial:

Request an Annual Quote

PDI Cuts Four Percent of Staff Ahead of Commercial Services Divestiture

NEW YORK (GenomeWeb) – PDI has cut four percent of its workforce, including employees from its soon-to-be-divested commercial services business and its core diagnostics segment, in a move the firm expects to trim $1.9 million from its yearly operating costs. 

Last month, PDI announced that it signed a deal to sell its commercial services business, which provides biomedical commercialization and marketing services, to Publicis Group for up to about $48 million. The deal, which is expected to close by the end of the month, stemmed from PDI's decision to focus on its molecular diagnostics operations.

PDI also said that it would assume the name of its molecular diagnostics subsidiary, Interpace Diagnostics, and change its Nasdaq trading symbol to IDXG when the deal is finalized.

In anticipation of the sale and in an effort to streamline its cost structure, PDI has cut 36 employees, representing two percent of its commercial services staff and 21 percent of Interpace Diagnostics, effective today, the company disclosed in a filing with the US Securities and Exchange Commission.

PDI said that the layoffs will save about $400,000 this month until the close of the Publicis deal, and $1.9 million annually for its ongoing Interpace segment.

In connection with the reduction in workforce, PDI said that it expects to incur a restructuring charge of about $1 million during the fiscal year ended Dec. 31. About 82 percent of this charge is directly attributable to the commercial services segment and would have been incurred as part of the sale, but is being recognized earlier to attain additional cost savings, the firm noted in the SEC filing.

The Scan

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.

Breast Cancer Risk Gene Candidates Found by Multi-Ancestry Low-Frequency Variant Analysis

Researchers narrowed in on new and known risk gene candidates with variant profiles for almost 83,500 individuals with breast cancer and 59,199 unaffected controls in Genome Medicine.

Health-Related Quality of Life Gets Boost After Microbiome-Based Treatment for Recurrent C. Diff

A secondary analysis of Phase 3 clinical trial data in JAMA Network Open suggests an investigational oral microbiome-based drug may lead to enhanced quality of life measures.

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.